

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**BS**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 5/00	A1	(11) International Publication Number: WO 91/09936 (43) International Publication Date: 11 July 1991 (11.07.91)
(21) International Application Number: PCT/US90/07630 (22) International Filing Date: 21 December 1990 (21.12.90) (30) Priority data: 456,757 26 December 1989 (26.12.89) US (71) Applicant: HANA BIOLOGICS, INC. [US/US]; 850 Marina Village Parkway, Alameda, CA 94501 (US). (72) Inventors: BOSS, Barbara, D. ; 308C Central Avenue, Alameda, CA 94501 (US). SPECTOR, Dennis, H. ; 5309 Locksley Avenue, Oakland, CA 94618 (US). (74) Agents: TERLIZZI, Laura et al. ; Skjerven, Morrill, Macpherson, Franklin & Friel, 25 Metro Drive, Suite 700, San Jose, CA 95110 (US).		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: PROLIFERATED NEURON PROGENITOR CELL PRODUCT AND PROCESS (57) Abstract This invention is based on the development of procedures for isolation and proliferation of neuron progenitor cells and is directed to growth, storage, production and implantation of proliferated neuron progenitor cells. The isolation and culture methods are designed to proliferate mammalian ventral mesencephalon neuron progenitor cells <i>in vitro</i> to produce a culture which differentiates to produce dopamine-producing cells. The products of this invention include a culture containing neuron progenitor cells, preferably, grown as aggregates in suspension cultures. The process of this invention for preparing neuron progenitor cells comprises obtaining ventral mesencephalon tissue from a donor at the appropriate stage of embryonic development; dissociation of the tissue to obtain single cells and small cell clusters for culture; culturing the neuron progenitor cells in an initial culture medium which selects for a novel cell culture containing neuron progenitor cells and growing the cells for a period of time in a second medium, during which the neuron progenitor cells proliferate.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

PROLIFERATED NEURON PROGENITOR CELL PRODUCT AND PROCESS

I

FIELD OF THE INVENTION

This invention relates to preparation of proliferated neuron progenitor cells and their implantation. In particular, this invention relates to processes for producing proliferated neuron progenitor cells which can be induced *in vivo* or *in vitro* to develop into functional neurons which produce dopamine.

BACKGROUND OF THE INVENTION

The nervous system contains two classes of cells: the nerve cells (or neurons) and neuroglia cells (or glia). These cells are distinguished by morphological, biochemical and functional differences. Morphologically, neurons have a cell body and projecting extensions or neurites (processes) of varying length. *In vivo*, neuritic extensions are further divided into axons (which transfer signals away from the neuron) and dendrites (which transfer signals to the neuron). Among many other biochemical and biophysical processes, neurons synthesize specific chemicals involved in signaling of information. In the central nervous system (CNS) glia are nine times more prevalent than nerve cells. Glia are thought to serve as neural supportive elements by providing nutrients, growth or survival factors and extracellular matrices. These cells are morphologically distinct from nerve cells and do not synthesize neurotransmitters.

To date, attempts to implant functional neuronal cells have largely been unsuccessful. Once the cells send out neurites *in vivo*, they are very difficult to transplant. The neurites become damaged during preparation of the implantation culture, leading to the death of the cells. In response to this problem, cells for implantation have been obtained from embryos at a point in the embryonic maturation process prior to neurite formation to eliminate cell death due to disruption of the neurites.

However, it is also undesirable to transplant fresh tissue. A period of time to evaluate the tissue prior to implantation, such as to determine whether the tissue is contaminated with a virus, is highly desirable. To hold the tissue for a period of time, the tissue must either be cultured *in vitro* or frozen. Fresh tissue is fragile, and does not respond well to freezing.

2

The percentage of viable cells in the fresh tissue is greatly diminished by the freeze/thaw process so that a substantial percentage of the cells in the implant are nonviable. In response to the problems inherent in using fresh or fresh-frozen tissue, attempts to culture undifferentiated cells *in vitro* for implantation have been performed.

Since the initial discovery 80 years ago by Ross Harrison that nerve fibers can survive under tissue culture conditions, the literature has become inundated with reports using cultured nervous tissue. Neuronal cells *in vitro* also send out neurites, leading to the same problems of cell death upon disruption of the neurites as encountered with fresh tissue. Therefore, attempts to transplant cells prior to production of the neurites *in vitro* have been made.

The consensus in the reports regarding dissociated CNS tissue (single cell suspension) is that (1) tissue derived from CNS areas which are no longer displaying neuronal division *in vivo* will only support glial survival *in vitro* (see, for example, Hansson et al., *Brain Research* 300:9-18 [1984]) and (2) tissue derived from CNS areas still undergoing neuronal division *in vivo* will allow both neuronal and glial survival *in vitro*; those neurons will not proliferate, but can differentiate to varying degrees under *in vitro* conditions (see for example, Ahnert-Hilger et al., *Neuroscience* 17(1):157-165 [1986] and Boss et al., *Dev. Brain Res.*, 36:199-218 [1987]).

Methods which produce cell cultures *in vitro* in which neuronal cells proliferate are being sought. The method should also minimize the cell loss due to disruption of neurites upon preparation of the cells for implantation. In particular, such cell cultures which would produce dopamine following implantation are highly desirable.

DESCRIPTION OF THE PRIOR ART

A few reports have claimed that a small proportion (6-15%) of neuroblasts obtained from embryonic chick or rat cerebral hemispheres can proliferate under *in vitro* conditions (see Barakat et al., *Neurochem. Research* 7(3):287-300 [1982]; Kriegstein et

al., *Brain Research* 295:184-189 [1984]; Asou et al., *Brain Research* 332:355-357 [1985]; Yoshida et al., *Neurosci. Letters* 70:34-39 [1986]). Temple, *Nature* 340:471-473 (1989) reports that individual CNS blast cells isolated from 13.5 to 14.5 day rat forebrain septal region and cultured as single cells in the presence of conditioning cells can divide and differentiate into neuronal cells, glial cells or both.

Buse et al., *Int. J. Devel. Neuroscience* 7:103-113 (1989) report that in cultures of ventricular cells from the rostral part of the mouse neural plates, ventricular cells developing into neuronal phenotypes immediately stopped proliferating upon transfer to cell culture, while a small portion of cells continued to proliferate, displaying morphological characteristics of radial glial cells. The authors conclude that two types of progenitor cells, committed to either neuronal or glial lineages, coexist in cultured neural plate cells.

Others (Honegger et al., *Nature* 282:305-307 [1979]), using re-aggregates of dissociated fetal rat brain cells, have demonstrated proliferation (but not specifically neuroblast proliferation) as well as differentiation under the same serum-free conditions. Still other workers (Frederiksen et al., *Soc. Neurosci. Abstr.* 12:1122 [1986]), unable to find significant proliferation *in vitro* of isolated rat progenitor cells, have turned to genetic manipulation of the cells (using retroviral insertion of oncogenes) to study early developmental events in the CNS.

In a recent article, Wes et al., *J. Cell. Physiol.* 36:367-372 (1988) stated that there is a general consensus that neuroblasts from embryonic rat brains do not divide in culture, despite reports that contradict this belief.

Regarding transplantation of progenitor cells, Doering et al., *Dev. Brain Res.* 5:229-233 (1982) have cultured subventricular epithelial cells from the embryonic mouse neopallium (dorsal cerebral cortex or neocortex) without showing any evidence of proliferation and transplanted these cells into the cerebella of neonatal mice. The transplanted developing cerebral cortical cells differentiated into their normal phenotypes *in vivo*, even

4

though misplaced in the cerebellum, but failed to differentiate properly under *in vitro* conditions.

Cultured embryonic cells have also been used as transplants intended to alter the unusual turning behavior demonstrated by
5 rats injected unilaterally with 6-hydroxydopamine (6-OHDA) (one of the animal models for Parkinson's disease). Brundin et al., *Neurosci. Letters* 16:79-84 (1985) used dissociated rat ventral mesencephalon cells cultured for six days and transported for two
10 of five transplanted animals showed behavioral recovery, with only 1 in 1000 of the cultured cells surviving as tyrosine-hydroxylase (TH)-positive neurons in the grafts after seven weeks *in vivo*. No claims were made by the authors that the cells in culture had proliferated to any significant extent.

15 Kamo et al. *Brain Res.* 397:372-376 (1986), also making no claims regarding proliferation, cultured explants of fetal human paravertebral sympathetic ganglion chains for three weeks to three months prior to using them as aggregates of 1000-4000 neurons for
20 transplantation in their 6-OHDA rat model. Four out of the six transplanted rats showed behavioral recovery as well as surviving TH-positive neurons in the graft (no quantitation reported). Although no immunosuppression was used in these experiments, five out of six grafts, analyzed after 4.5 to 6.0 months, contained
25 surviving TH-positive neurons.

SUMMARY OF THE INVENTION

This invention is based on the development of procedures for isolation and proliferation of neuron progenitor cells and is directed to growth, storage, production and implantation of
30 proliferated neuron progenitor cells. The isolation and culture methods are designed to proliferate neuron progenitor cells *in vitro* to produce a culture which differentiates to produce dopamine-producing cells. Depending on the culture period and conditions, the progenitor cells differentiate either *in vitro* or
35 *in vivo*, following implantation. In addition to increasing the number of neuronal cells, the cultures can be frozen while substantially maintaining cell viability. When cultured as

5

aggregates, the progenitor cell cultures send out neurites which are contained within the aggregates and therefore are not disrupted in the implantation process. Thus, a high percentage of viable cells is maintained.

5 A portion of the neuron progenitor cells spontaneously differentiate *in vitro*. Following implantation, a subpopulation of the neuron progenitor cells which did not differentiate *in vitro* differentiate *in vivo* and function as tyrosine hydroxylase-containing neurons, gaining the ability to produce functional
10 effects by about three to six months following implantation, depending on the species of donor and host tissue. Alternatively, the neuron progenitor cells can be induced to differentiate *in vitro*, producing a population of mature neurons which produce dopamine.

15 The products of this invention include a culture containing neuron progenitor cells. The culture can be progenitor cells or aggregates of progenitor cells in a culture medium, or single or aggregated neuron progenitor cells on or dispersed in a substrate matrix. Most preferably, the cultures are suspension cultures in
20 which the progenitor cells grow as aggregates.

The process of this invention for preparing neuron progenitor cells comprises obtaining ventral mesencephalon tissue from a mammalian donor at the appropriate stage of embryonic development; dissociation of the tissue to obtain single cells and
25 small cell clusters for culture; culturing the neuron progenitor cells in an initial culture medium which selects for a novel cell culture containing neuron progenitor cells (adaptive period) and growing the cells for a period of time (growth period) in a second medium. During the growth period, the neuron progenitor cells
30 proliferate. The progenitor cells differentiate *in vivo*, following implantation and can be induced to differentiate *in vitro* by addition of a differentiation agent; e.g., cyclic AMP.

DETAILED DESCRIPTION OF THE INVENTION

35 The present invention is based on the development of a method for isolating, culturing and proliferating neuron progenitor cells *in vitro*. The isolation and culture methods are

6

designed to proliferate neuron progenitor cells *in vitro* to produce a culture having an increased number of neuron progenitor cells. Progenitor cells in the culture can differentiate to produce dopamine-producing cells *in vitro*, depending on the culture period and conditions, or can differentiate *in vivo*, following implantation.

In addition to increasing the number of neuronal cells through proliferation, the cultures can be frozen while substantially maintaining cell viability. When grown as aggregates, the progenitor cell cultures send out neurites which are not disrupted in the implantation process, thus maintaining a high percentage of viable cells upon implantation. Following implantation, a subpopulation of progenitor cells which did not differentiate *in vitro* differentiate *in vivo* and function as tyrosine hydroxylase-containing neurons, gaining the ability to produce functional effects about three to six months following implantation, depending on the species of the implanted tissue and of the host.

In addition to its use as an implant, a culture of this invention can be used for evaluating agents which inhibit or enhance neuroblast proliferation or differentiation or for evaluating the toxicity of an agent on neurons. Aggregate cultures are particularly advantages for these purposes. Methods for evaluation of pharmacological agents using cell cultures are well known and involve combining the agent with the culture and observing the effect of various concentrations of the agent on the cultured cells.

The process of this invention for preparing neuron progenitor cells comprises obtaining ventral mesencephalon tissue from a mammalian donor at the appropriate stage of embryonic development; dissociating of the tissue to obtain single cells and small cell clusters for culture; culturing the neuron progenitor cells in an initial culture medium which selects for a novel cell culture containing neuron progenitor cells and maintaining the culture for a period of time in a second medium during which the neuron progenitor cells proliferate.

7

As used herein, the following terms are defined as follows:

"Cell culture" or "tissue culture" refers to the maintenance of cell viability and function *in vitro*. It may or may not involve cell proliferation.

5 "Cell proliferation" is a process of cell multiplication by means of cell division. When this occurs *in vitro* to any significant level in monolayer cultures, it usually involves one or more subcultures.

10 "Subculture" means the transfer of cells from one culture vessel to another. The term is synonymous with the term "passage".

"Graft" is a cell culture which has been implanted into a host animal.

15 Key steps for culturing neuron progenitor cells are described in detail below. While the steps are provided in some detail, it will be readily apparent to a person skilled in the art that the procedures described can be modified and varied without departing from the objective thereof, and this invention is not
20 limited to the specific details presented herein.

PREPARATION OF NEURON PROGENITOR CELL CULTURE

Embryonic mammalian tissue is used to prepare neuron progenitor cell cultures. The tissue can be from any mammalian
25 source, conveniently from a large mammal. Preferably, the tissue is from a goat, cow, sheep or other commercially raised animal. Most preferred is the use of human or porcine tissue.

The donor embryo is in the early stages of development, prior to neurite formation. The tissue is removed from the
30 dopaminergic system of the brain. Preferably, the tissue is from an area which differentiates to form an area of the brain with a relatively high concentration of TH-positive neurons. Most preferably, the tissue is from the ventral mesencephalon.

The objective of the tissue preparation procedure is to
35 disperse the tissue into single cells and small aggregates (about 500 cells per aggregate) without prolonged exposure conditions that impair cell viability. A description of two tissue

B

dissociation methods, mechanical and enzymatic, are described. Mechanical dissociation is preferred since the process is as effective as enzymatic digestion and avoids cell viability impairment caused by exposure to enzymes.

5 Also described is preparation of monolayer cultures and suspension (aggregate) cultures from the dissociated cells. Aggregate cultures are preferred for implantation, since the procedure allows neuron progenitor cell differentiation within the aggregates during the culture period without disruption of
10 neurites during the implantation process. The aggregate size is controlled by the culture conditions. Preferably, culture conditions are used so that the size of the aggregates remains small enough to implant by injection through a catheter. Aggregate cultures conveniently range in size from about 100 to
15 about 1000 microns.

 The neuron progenitor cell culture aggregates have loci of undifferentiated cells and loci of neurons. The loci of undifferentiated cells may contain rosette-like structures in which mitotic figures are often seen. The loci of neurons contain
20 TH-positive cell bodies whose neurites appear to extend to the periphery of the aggregates. Upon histological examination, the aggregates appear to be bordered by a layer of neuropil (an acellular, neurite-rich area).

 Preparation of monolayer cultures is also described.
25 Monolayer cultures may be advantageous for procedures in which selection of certain populations of cells is desired. The selected cells can be implanted or cultured as aggregates. Monolayers which will be implanted without intermediate culture as aggregates are preferably grown on a substrate which can be
30 removed from the culture vessel and implanted, such as amniotic membranes, rather than a substrate where enzymatic digestion is required to remove the cell culture for implantation.

 Gross examination of typical neuron progenitor cell
35 "monolayer" cultures reveals interconnected three-dimensional structures, rather than the usual two-dimensional monolayer observed with most cell lines. It is thought that the proliferative capacity of these cells creates this three-

9

dimensional effect. Over time, cells begin to migrate from these structures and form typical two-dimensional monolayers in which differentiating neurons and glia can be observed.

5 If desired, prior to implantation, neuron progenitor cell cultures can be successfully frozen and stored at the time of dissociation or following the completion of the selection period. The cultures can be induced to differentiate *in vitro* at any time.

10 In addition to being observably different from prior art neuron cell cultures, the neuron progenitor cell cultures of this invention are biochemically distinguishable from freshly prepared ventral mesencephalon cultures. In particular, for the same amount of embryonic tissue, a neuron progenitor cell culture of this invention produces approximately 100-fold the amount of catecholamines. Following *in vitro* differentiation, the cultures
15 produce approximately ten-fold the amount of catecholamines of the non-differentiated cultures. In addition, the ratios of concentrations of the three major brain catecholamines (dopamine, epinephrine and norepinephrine) changes following differentiation.

20

Isolation of Tissue

Removal and Storage of Embryos

- 25 1. Remove embryos in amniotic sacs from uterus by sterile lavage with 0.15 M NaCl. Use embryos at Carnegie stages 15-18 for porcine or human tissue. (An explanation of the Carnegie stages can be found in "Developmental Stages in Human Embryos" by Ronan O'Rahilly and Fabiola Muller, Carnegie Institution of Washington (Carnegie Laboratories of Embryology, California Primate Research Center and Departments of
30 Human Anatomy and Neurology; University of California, Davis) Publication 637, 1987 and "An Atlas for Staging Mammalian and Chick Embryos by H. Butler and B.H. Juurlink 1987, CRC Press, Inc.)
- 35 2. Store embryos in sterile "Transport Medium" (Jawamoto et al, *Brain Res.*, 384:84-93 [1986] - Formula: 54 mM KH_2PO_4 , 30 mM K_2HPO_4 , 195 mM D-sorbitol, 5 mM D-glucose, 20 mM sodium lactate, 50 $\mu\text{g/ml}$ gentamicin) at 4°C for

/0

up to 72 hours before proceeding with the cell preparation. That article is incorporated herein by reference in its entirety.

3. All subsequent procedures are performed aseptically.

5

Dissection of Embryos

1. Remove embryos from amniotic sac.
2. By fine dissection with forceps, peel back the skin from the head of the embryo to expose the meninges and the brain. At this time the fine curvatures of the brain surface and the numerous blood vessels on it will be apparent.
3. Make the first cut, a cross-section through the neural tube, immediately posterior to the isthmus separating the mesencephalon from the metencephalon.
4. Make cuts number 2 and number 3, which separate the dorsal region of the mesencephalon from the ventral region, and discard the dorsal segments.
5. Make cut number 4, at 90° from cut number 1, a cross-section through the neural tube anterior to the mesencephalon, releasing the ventral mesencephalon (VM). Tease away any membranes that are still attached.
6. An ideal VM section should be opaque, white in color, very soft in texture, and shaped roughly like a butterfly. Any trace of clear or semi-clear tissue (i.e. meninges) should be removed from the VM section.
7. Pool dissected VM pieces in a small drop of Hanks Basal Salt Solution (HBSS) (per liter: 0.14 g CaCl_2 ; 0.06 g KH_2PO_4 ; 0.4 g KCl ; 0.1 g $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$; 0.1 g $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$; 8.00 g NaCl ; 0.35 g NaHCO_3 ; 0.09 g $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$; 1.0 g D-glucose; 0.01 g phenol red) containing 50 $\mu\text{g/ml}$ gentamicin and 50 mM Hepes buffer, pH 7.2 (Hanks/Hepes/gentamicin, hereinafter HHG). Keep pieces on ice in a small petri dish.

11

For human tissue, the dissection is essentially the same, but will first require a three-dimensional "reconstruction" of the tissue if it is not intact in order to visualize and identify the region of the mesencephalic flexure.

5 Following isolation of the tissue, the tissue is dissociated into single cells and small aggregates of cells (less than about 500 cells per aggregate). The dissociation can be by enzymatic or mechanical methods, or a combination thereof. Exemplary enzymatic and mechanical methods are described below. Following
10 dissociation of the cells, the cells are cultured as monolayers or, preferably, in suspension cultures in which the cells form aggregates (aggregate cultures). Each cell culture type is described using a different dissociation procedure. However, any
15 dissociation procedure can be used to prepare monolayer or aggregate cultures.

Aggregate cultures are seeded by placing a small number of cells in a small volume of medium, preferably 1.0 ml or less, more preferably less than 0.5 ml. Not more than about 10^5 cells, preferably fewer than 10^4 cells are seeded per culture. In a most
20 preferred embodiment, from about 2.5×10^3 to about 5×10^3 cells per well are seeded in each well of a 48 well plate. Using seeding conditions that control the initial number of cells per culture tends to control the eventual size of the aggregates. In
25 addition, use of smaller initial seeding concentrations produced smaller aggregates and enhanced the viability of the aggregates. Specifically, the absence of necrotic cells in the centers of the aggregates correlated with lower initial plating densities and maintaining smaller aggregate size.

In the culture process of this invention, the cultures are
30 initially grown in a first culture medium which promotes the survival of neuron progenitor cells which are capable of proliferating in a serum-free, defined medium. The initial culture medium can be a basal medium supplemented with serum, hormones, growth factors and trace elements. Alternatively, the
35 initial culture medium can be a basal medium supplemented with fetal cord serum, preferably from the same species as the cultured cells. Ham's F12 with 5% fetal cord serum is an effective initial

12

culture medium. Preferably, the initial culture medium is Ham's F12 with Chang's supplement C (hereinafter Chang's) or a medium having a similar composition. Chang's is preferably present at about 5% (v/v) or more. In a most preferred embodiment, the
5 initial culture medium additionally contains glutamine at a concentration of about 2 mM and superoxide dismutase at about 100 U/ml. The cultures remain in the initial culture medium for at least 4.5 days prior to culture in growth medium. The growth medium is preferably added by day 7, but more preferably between
10 days 4.5 to 5.5.

Mechanical Dissociation of Cells

Preparation of Aggregate Culture

1. The tissue is dissected as described above.
- 15 2. Collect tissue sections in a small (about 50 μ l) drop of HHG in a small petri dish on ice.
3. Pool all sections in 1 drop of HHG, and chop into pieces 0.5 mm or smaller. Keep this on ice.
- 20 4. Remove the cap from a 50 ml centrifuge tube, place a 7x7 cm autoclaved 210 μ mesh Nitex screen (Tetko cat. no. 3-210/36) over the opening and secure it in place with an autoclaved rubber band.
5. Repeat step 4 with a second centrifuge tube using a 130 μ mesh Nitex screen (Tetko cat. no. 3-130/43).
- 25 6. Place 10 ml room temperature HBSS in a 15 ml centrifuge tube that had been rinsed with 4% bovine serum albumin (BSA) in HBSS (hereinafter HBSS/BSA) to form a BSA-coated tube. Add 0.1 ml of DNase stock. (DNase stock is Sigma cat. no. D4527 DNase at 1 mg/ml in HBSS.)
- 30 7. Place the tip of a sterile pasteur pipet into the flame of a burner so that melting of the tip closes the opening. Then heat the pipet at about 0.5 cm above the melted tip so that a hook is formed. Coat this pipet by dipping the hooked tip in HBSS/BSA.
- 35 8. Using an unaltered, BSA-coated pasteur pipet, transfer the tissue fragments onto the center of the 210 μ

13

Nitex screen. Wash the tissue with about 2 ml of HHG, then remove as much liquid as possible from the screen with the pipet. Combine this liquid with the HBSS/DNase solution.

- 5 9. Using the curve on the hooked Pasteur pipet and a gentle scraping movement, work the tissue through the screen quickly, but gently, to prevent the tissue from drying.
- 10 10. Wash the screen with the DNase stock solution. Keep the wetted area to a minimum on the center of the screen.
- 15 11. Repeat steps 9 and 10 until no more tissue fragment is visible on the screen, using not more than 6 ml of the DNase stock solution.
- 20 12. Remove all liquid from the 210 μ screen. Then carefully remove the rubber band and the screen.
- 25 13. Transfer the cell suspension to the center of the 130 μ screen using the unaltered BSA-coated pipet. Then repeat steps 9 through 12, using the remainder of the DNase stock solution.
- 30 14. Transfer the cell suspension from the tube with the 130 μ screen to the BSA-coated 15 ml tube (now empty of DNase stock solution). Then centrifuge at 150 \times g for 3 minutes.
- 35 15. Discard supernatant. Resuspend cells in suitable volume of an appropriate medium, preferably the initial culture medium. In general, 0.5-1.0 ml of F12 + 5% Chang's supplement C + 2 mM glutamine + 100 U/ml Superoxide Dismutase is an appropriate volume of a most preferred initial culture medium. (Chang's supplement C is commercially available from Irvine Scientific; Irvine, CA).
- 40 16. Remove 10 μ l of cell suspension after gentle trituration. Add this to 40 μ l of 0.04% Crystal Violet solution, then triturate with a micropipeter until a single nuclear suspension is obtained (about 100 \times). Count using a hemacytometer.

14

17. Gently triturate the cells before diluting to appropriate volume for seeding. Usually seeding is done at 3×10^3 cells in 0.3 ml in each well of a 48 well plate.
- 5 18. Various volumes of medium can be added 2 hours later to control aggregate formation. In particular, a volume of 0.45 ml yields single aggregates in each well of a 48 well plate. Volumes greater than 0.30 ml but less than 0.35 ml yield multiple aggregates in
- 10 each well. These volumes were determined at 270 rpm on a mini-orbital shaker (Bellco; Vineland, NJ). A speed of 180 rpm will yield single aggregates at various volumes. Sylgard 184 (Dow Corning Corp.; Midland, MI) coating of the wells may be necessary to
- 15 inhibit aggregate adhesion to the well (particularly for human tissue).
- Switch medium to HN2 Medium 5 days later by removing about half of the medium and adding that volume of HN2 medium. Then feed about twice a week with HN2 Medium by removing approximately half of the
- 20 medium and replacing that volume with fresh medium. Alternatively, the initial medium can be exchanged for HN2 medium at 5 days and half or all of the medium replaced for subsequent feedings. HN2 medium is a
- 25 modified version of N2 medium (Bottenstein and Sato, *PNAS* 76:514-517 [1979]) which contains 1:1 v/v Dulbecco's Modified Eagle Medium (Dulbecco et al., *Virology* 8:396 [1959]):Ham's F12 (Ham, *PNAS* 53:288 [1965]). Those articles are incorporated herein by
- 30 reference in their entirety. The formulae for each of the components of HN2 are shown below. HN2 Medium contains DMEM (low glucose):F12 1:1 v/v and the additional ingredients shown in Table 1. The formulae for DMEM and F12 are found in Tables 2 and 3,
- 35 respectively.

15

TABLE 1
HN2 Medium
DMEM (low glucose):F12 1:1 v/v

5	COMPONENT	CONCENTRATION
	<u>N2 medium</u>	
	insulin	5 $\mu\text{g/ml}$
	transferrin	100 $\mu\text{g/ml}$
	putrescine	100 μM
10	selenium	30 nM
	progesterone	20 nM
	<u>additional components</u>	
	glutamine	2 mM
15	KCl	25 mM
	human serum albumin	0.1% (g/100 ml)

16

TABLE 2
DULBECCO'S MODIFIED EAGLE MEDIUM¹
Low Glucose

5	COMPONENT	mg/L
	Inorganic salts:	
	CaCl ₂ (anhyd.)	200.00
	Fe(NO ₃) ₃ •9H ₂ O	0.10
	KCl	400.00
10	MgSO ₄ •7H ₂ O	200.00
	NaCl	6400.00
	NaHCO ₃	3700.00
	NaH ₂ PO ₄ •H ₂ O	125.00 ²
	Other components:	
15	D-Glucose	1000.00
	Phenol red	15.00
	Sodium pyruvate	110.00
	Amino Acids:	
	L-Arginine HCl	84.00
20	L-Cystine	48.00
	L-Glutamine	584.00
	Glycine	30.00
	L-Histidine HCl•H ₂ O	42.00
	L-Isoleucine	105.00
25	L-Leucine	105.00
	L-Lysine HCl	146.00
	L-Methionine	30.00
	L-Phenylalanine	66.00
	L-Serine	42.00
30	L-Threonine	95.00
	L-Tryptophan	16.00
	L-Tyrosine	72.00
	L-Valine	94.00
	Vitamins:	
35	D-Ca pantothenate	4.00
	Choline chloride	4.00

17

TABLE 2 (continued)

	COMPONENT	mg/L
	Folic acid	4.00
	i-Inositol	7.20
5	Nicotinamide	4.00
	Pyridoxal HCl	4.00
	Riboflavin	0.40
	Thiamine HCl	4.00
10	¹ Dulbecco et al., <i>Virology</i> 8:396 (1959); Smith et al., <i>Virology</i> 12:185-196 (1960); Tissue Culture Standards Committee (TCSC), <i>In Vitro</i> 6(2):93 (1970).	
	² Value shown is in conformance with the TCSC, <i>In Vitro</i> , 9, No. 6 (1970).	

15

18

TABLE 3
F12 MEDIUM

	COMPONENT	mg/L
5	Inorganic salts:	
	CaCl ₂ •2H ₂ O	44.00
	CuSO ₄ •5H ₂ O	0.00249
	FeSO ₄ •7H ₂ O	0.834
	KCl	223.60
10	MgCl ₂ •6H ₂ O	122.00
	NaCl	7599.00
	NaHCO ₃	1176.00
	Na ₂ HPO ₄ •7H ₂ O	268.00
	ZnSO ₄ •7H ₂ O ¹	0.863
15	Other components:	
	D-Glucose	1802.00
	Hypoxanthine	4.10
	Linoleic acid	0.084
	Lipoic acid	0.21
20	Phenol red	1.20
	Putrescine 2HCl	0.161
	Sodium pyruvate	110.00
	Thymidine	0.73
	Amino Acids:	
25	L-Alanine	8.90
	L-Arginine HCl	211.00
	L-Asparagine•H ₂ O ¹	15.01
	L-Aspartic acid	13.30
	L-Cysteine HCl•H ₂ O	35.12
30	L-Glutamic acid	14.70
	L-Glutamine	146.00
	Glycine	7.50
	L-Histidine HCl•H ₂ O	20.96
	L-Isoleucine	3.94
35	L-Leucine	13.10
	L-Lysine HCl	36.50

19

TABLE 3 (continued)

	COMPONENT	mg/L
	L-Methionine	4.48
	L-Phenylalanine	4.96
5	L-Proline	34.50
	L-Serine	10.50
	L-Threonine	11.90
	L-Tryptophan	2.04
	L-Tyrosine	5.40
10	L-Valine	11.70
	Vitamins:	
	Biotin	0.0073
	D-Ca Pantothenate ¹	0.4800
	Choline chloride	13.9600
15	Folic acid	1.300
	i-Inositol	18.000
	Niacinamide	0.0370
	Pyridoxine HCl	0.0620
	Riboflavin	0.0380
20	Thiamine HCl	0.3400
	Vitamin B ₁₂	1.3600

¹Value established by the TCSC.

- 25 HN2 medium is prepared in polycarbonate tubes and filter sterilized using Millex yellow (i.e. "protein" non-absorbing) filters (Millipore Corp., Bedford, MA). The medium is stored not more than 2 days at 4°C prior to use.

30

Enzymatic Dissociation of Cells
Preparation of Monolayer Culture

1. Pool all dissected sections in a drop of HBSS. Chop into pieces not greater than about 0.5 mm with small razor blade holder.
- 35 2. Transfer pieces to a 15 ml tube previously rinsed with 4 ml of HBSS/BSA, using a Pasteur pipet previously washed with HBSS/BSA.

20

3. Centrifuge cells at 75xg for 2 minutes.
4. Resuspend the pellet in a minimum of 0.5 ml Dispase (Collaborative Research cat. no. 40235). This is sufficient volume for less than 5 embryos (as starting material). For 10 embryos, use 1 ml, etc.
5. Incubate 20 minutes at 37°C with gentle shaking every 5 minutes to resuspend pieces.
6. Add 2 ml HBSS/BSA for every 0.5 ml Dispase.
7. Centrifuge cells at 75xg for 2 minutes.
8. Aspirate supernatant and discard.
9. Resuspend pellet in 0.9 ml HBSS + 0.1 ml DNase stock solution. Gently triturate with a BSA-coated, fire-polished Pasteur pipet (bore reduced to about half of its normal diameter) until a homogeneous solution is obtained. Do not leave the cells in the DNase stock solution for more than 5 minutes.
10. Layer cell suspension over 4 ml of HBSS/BSA.
11. Centrifuge at 119xg for 15 minutes.
12. Aspirate the supernatant and discard. Resuspend the cell pellet in culture medium with the BSA-coated, fire-polished Pasteur pipet.
13. Count cells with a hemacytometer.
14. Before proceeding with cells triturate again with BSA-coated Pasteur pipet as cells clump rapidly upon standing.

Seeding Neural Epithelial Cells for Monolayer Cultures

1. Resuspend isolated cells at 5×10^5 cells/ml in F12 medium (Gibco cat. no. 320-1765) containing 5% v/v Chang's Supplement C (Irvine Scientific), and 2 mM glutamine (hereinafter F12 + 5% Chang's).
2. Seed cells on poly-l-ornithine coated (see below) tissue culture plastic at 0.85×10^5 cells/cm².
Poly-l-ornithine coated plastic:
Prepare plastic the day prior to use. Dilute stock poly-l-ornithine (1.0 mg/ml poly-l-ornithine, Sigma P-2533 in sterile 0.2 M borate

21

buffer, pH 8) 1:250 v/v in sterile borate buffer. Add an appropriate volume to surface to be coated and incubate 4 hours at 37°C. Transfer plates to 4°C for overnight storage. Aspirate poly-l-ornithine off the plate and rinse three times with sterile H₂O before use.

5

10

15

3. The day after seeding cells, add an appropriate volume of fresh F12 + 5% Chang's to the cultures. On day 5 after seeding and every 3 to 4 days thereafter exchange feed, i.e., remove half of the "old" medium and replace with fresh HN2 Medium. When switching the initial culture medium to the growth medium, either all of the medium can be replaced or, preferably, half of the medium can be replaced with new HN2 Medium being used at each subsequent feeding.

Passaging Neural Epithelial Cells

20

25

30

35

1. Depending on growth, subculture prior to extensive neurite formation.
2. Pool media from wells or plates. Wash each well or plate containing attached cells one time gently with calcium-free, magnesium-free Hanks Basal Salt Solution (CMF-HBSS) and add to above medium.
3. Centrifuge 75×g for 2 minutes at room temperature. Resuspend the pellet in 0.5 ml 0.02% ethylenediamine tetraacetic acid (EDTA), 0.05% trypsin in CMF-HBSS (trypsin-EDTA). Incubate 37°C for 5 minutes.
4. To washed, attached cells, add an appropriate volume of trypsin-EDTA. When passaging primary and secondary cultures, incubate at 37°C for 10 to 15 minutes. For later passages, incubate only 5 minutes.
5. Pool trypsinates. Wash wells with F12 + 5% Chang's and add to trypsinate. Add F12 + 5% Chang's to equal the volume of the trypsinate.
6. Centrifuge at room temperature at 150×g for 2 minutes.

22

7. Resuspend the pellet in 0.75 ml HBSS and triturate with fine bore or very fine bore Pasteur pipet just until clumps disappear, usually not more than 20 times.
- 5 8. Add 0.75 ml F12 + 5% Chang's and layer on top of 4 ml of HBSS/BSA.
9. Centrifuge 119xg for 15 minutes.
10. Discard supernatant. Resuspend pellet in 0.75 ml F12 + 5% Chang's. Triturate ten times or so with very fine bore Pasteur pipet.
- 10 11. Count cells in a hemacytometer and resuspend in medium to 5×10^5 cells/ml. Plate on poly-l-ornithine coated plastic at 0.85×10^5 cell/cm².
12. Proceed as described for primary monolayer culture above or perform selection procedures, such as FACS (fluorescent-activated cell sorting) or magnetic bead antibody sorting, and reculture in monolayer as described above or reculture in aggregates as described. Following growth of the neuron progenitor cell cultures for 5-15 days, the cultures can be
15
20 implanted. When convenient, the cultures can be stored frozen prior to implantation. A preferred procedure and thawing cells is described below.

Freezing and Thawing Neural Epithelial Cells

25 The cultures can be frozen and thawed by the following procedure.

Freezing Cells

- 30 1. Cells from monolayer cultures are frozen by this procedure following the same procedure used for passaging cells. Aggregates are frozen in same medium, but need not be at any critical concentration of cells. They can be thawed back out as aggregates and recultured or transplanted.
- 35 2. Suspend cells in F12 + 5% Chang's + 2 mM glutamine medium (at about 2×10^7 /ml for trypsinates of monolayer cultures).
3. Cool on ice for about 5 minutes.

23

4. Add an equal volume of cold 20% dimethylsulfoxide (DMSO) in F12 + 5% Chang's dropwise while mixing for a final cell concentration of $10^7/\text{ml}$.
5. Incubate on ice for 30 minutes.
- 5 6. Aliquot into labeled, screw cap freezing vials. Label with cell type, passage number, date and volume frozen.
7. Transfer vials (wrapped in cotton) to a pre-cooled freezing carton at -20°C for 1 hour.
- 10 8. Transfer vials to a -80°C freezer overnight, then transfer to a liquid N_2 -containing dewar flask.

Thawing Cells

- I. Remove vials from liquid N_2 .
2. Thaw rapidly in 37°C water bath.
- 15 3. As soon as thawed (about 30 seconds for $150\ \mu\text{l}$), add an appropriate volume of F12 + 5% Chang's medium at 37°C to obtain final cell concentration of 2×10^6 cells/ml. At this point cells may be transplanted or passaged further. A preferred transplantation procedure is described below.
- 20 4. For passaging monolayer cultures, plate cells on poly-l-ornithine-coated plastic at 3.4×10^5 cells/ cm^2 .

IN VITRO DIFFERENTIATION OF PROGENITOR CELLS

- 25 Neuron progenitor cells can be induced to differentiate *in vitro* by adding a differentiation agent to the culture medium at an effective concentration for a time sufficient for progenitor cells in the culture to differentiate. A sufficient period of time can be determined by monitoring the cultures for a
- 30 significant increase in levels of TH or dopamine.

Differentiation agents include sodium butyrate, butyric acid, cyclic adenosine monophosphate (cAMP) derivatives, phosphodiesterase inhibitors, adenylate cyclase activators and prostaglandins. Effective levels are determined empirically by

35 titration. A preferred differentiation agent is a cAMP derivative. Preferred cAMP derivatives are 8-bromo-cyclic AMP and di-butyryl-cyclic AMP (dbc-AMP). Most preferred is dbc-AMP at a

24

concentration in the range of from about 2 to about 5 mM (final concentration in the culture medium).

The differentiation agent can be added to the culture medium once the cells have been in growth medium for at least about five days. Preferably, the differentiation agent is added prior to ten days in growth medium. When the growth medium is replaced during the differentiation period, the replacement medium contains the differentiation agent. Differentiation is substantially complete following at least about seven days of continuous exposure to the differentiation agent. Seven days of use of the differentiation agent is optimal. Following completion of differentiation, the differentiation agent is preferably removed. Prolonged exposure to the agent may be toxic. Following completion of differentiation, differentiated progenitor cells in the culture cease proliferation and are preferably transplanted.

When using the differentiated cells for implantation, the time required to cure Parkinsonian symptoms is shorter than when undifferentiated progenitor cell cultures are implanted. Differentiated cells do not require an initial period of time *in vivo* to differentiate to gain the ability to produce tyrosine hydroxylase.

TRANSPLANTING NEURAL EPITHELIAL CELLS

The neuron progenitor cell cultures can be transplanted by well known procedures for implantation of neural tissue. A preferred procedure is described below. Following transplantation, neuron progenitor cells in the resultant grafts differentiate to produce their differentiated counterparts, neurons. A subpopulation of the neurons are TH-containing neurons which produce functional effects in the host animal.

Preparation of Cells for Transplantation

1. Cells can be transplanted by this procedure:
 - a. Immediately after isolation from the embryo;
 - b. After passaging;
 - c. After growth as an aggregate culture;
 - d. After freezing and thawing; or

25

e. After selection from a monolayer.

2. Resuspend cells at $1-5 \times 10^5$ cells/6 μ l of HBSS. Hold cells at 4°C throughout the transplantation procedure.

5 Transplantation Procedure

1. Weigh and inject the rat with the Ketamine/Xylazine cocktail (Ketamine: Parke-Davis (Vetalar) Morris Plains, NJ; Xylazine: Rugby (Gemini) Rockville Center, NY) by intraperitoneal (IP) or intramuscular injections to induce surgical anesthesia. IP injections have a quicker onset of action and produce surgical anesthesia for approximately 30-45 minutes.
2. At 5-10 minutes post injection, check the rat for tail reflex. Absence of a tail pinch reflex is a fairly reliable indication that the rat has reached surgical anesthetic plane. Whisker movement and strong corneal reflex are indicators that a supplementary dose should be given (0.05-0.10 ml Ketamine/Xylazine). The cocktail tends to produce a characteristic "bugging" of the eyes.
3. Shave the animal at the site of incision.
4. Due to the length of surgical procedure, rinse the rat's eyes with saline and place a drop of mineral oil in its eyes.
5. Position the rat in the ear bars of a Kopf stereotaxic apparatus by inserting one ear bar at a time into the auditory canal. Check the coordinate position of the incisor bar and then position it under the incisor teeth of the rat and pull taut. Close the nose clamp firmly but gently.
6. Make a 0.5" incision from eye midline to just above the ears. Cut the fascia in a crisscross pattern with the surgical knife and scrape the fascia away with a scalpel. Attach the hemostats to the remaining muscle and fascia at the borders of the incision to help reveal the skull surface. 70% alcohol-soaked applicators help to define the sutures. Bregma, lambda

26

and sagittal sutures should be visible if the incision was made correctly.

7. Draw up 6 μ l of cell suspension into a 10 μ l Hamilton syringe fitted with a 22 gauge, 1" long, blunt-end needle.

5

8. Mount the syringe in the syringe holder. Align the needle over the bregma suture. Coordinates relate to anatomical positions within the rat brain, as taken from a stereotaxic atlas. All numbers read on the stereotaxic apparatus. When needle is at bregma (the zero position in the anterior-posterior (AP) and medial-lateral (ML) directions) and skull surface (the Dorsal-Ventral (DV) zero coordinate), these are the zero coordinates. (In calculating the zero coordinate position, it may be necessary to take an average zero coordinate if a poor intersection coronal and sagittal of the sutures exist.) The transplant coordinates are added and/or subtracted from the zero settings. Moving to these coordinates will put the needle into the anatomical area of the brain that corresponds to the transplant coordinates taken from the atlas.

10

15

20

Calculate the surgical structure coordinates desired for the AP, ML positions. Again, lower the needle tip to the surface of the skull but this time at the needle entry site. Record the DV zero coordinates and then calculate the structure depth. Coordinates for transplant: AP + 1.0, ML 2.5, DV 6.2 and 4.5 from skull surface, with incisor bar at zero.

25

9. Mark the location of entry with a ball-point pen. Clear the needle and syringe out of the way by turning the DV knob in a counter clockwise direction and then drill a hole in the skull using a hand-driven pin vise and bit. Be careful to only drill through the skull and not through the dural membrane.

30

10. Lower the syringe to lowest of DV coordinates.
11. Inject 3 μ l of cells at each site, at a rate of 1 μ l/min. Wait 2 minutes before raising needle to second

35

27

site. Wait another 2 minutes before removing needle at a rate of 1 mm/min. Removal rate can be increased to 2 mm/min. for the last couple of millimeters.

- 5 12. Remove the rat from the stereotaxic device. Swab any clotted blood, apply wound powder, suture and reapply wound powder on the closed wound (Nitro-fur-wound powder; Life Science Products; St. Joseph, MO).

10 This invention is further illustrated by the following specific, but non-limiting examples. Unless otherwise specified, all temperatures are in degrees centigrade and all percentages are in weight percents. Procedures which have been reduced to practice are presented in the past tense, and procedures and products which are first reduced to practice in the filing of this
15 application are presented in the present tense.

EXAMPLE 1

Fixation of Brain

Rat brain tissue was fixed by the following procedure.

- 20 1. The rat is deeply anesthetized with pentobarbital.
2. Set the pump on 45 (about 30 ml/min) and prime the tube with 0.1 M phosphate buffered saline (hereinafter PBS or 0.1 M PBS) (Formula: 14.8 g NaH_2PO_4 , 4.3 g Na_2HPO_4 , 7.2 g NaCl for 1 L. of 0.1 M PBS).
25 3. Open the thoracic cavity, clamp off the descending aorta and insert the needle into the left ventricle. Cut a small hole in the right atrium and start the pump.
30 4. Perfuse 100-200 ml of PBS, turn off the pump, transfer the tube to the 4% paraformaldehyde without creating air bubbles, and restart the pump. Perfuse approximately 250 ml. Turn the pump off, disengage the needle, rapidly decapitate the rat, and dissect out the brain.
35 5. Place the brain in 4% paraformaldehyde (4% paraformaldehyde in 0.1 M PBS) for 2 hours. Wash in PBS and transfer to 30% sucrose with 0.1% sodium azide

28

overnight and hold no longer than 1 week for sectioning.

EXAMPLE 2

5

Sectioning of Fixed Brain Tissue

Brain tissue which was fixed according to the procedure in Example 1 was sectioned by the following procedure.

1. Cut into blocks about 7 mm thick.
2. Snap freeze blocks in dry ice/ethanol.
- 10 3. Cut frozen blocks on a sliding microtome at 40 μ .
4. Store sections at 4°C in 0.1 M PBS with 0.1% Na azide up to 2 weeks before staining for tyrosine hydroxylase (TH). For long term storage: 30% ethylene glycol, 25% glycerin in 0.05 M phosphate buffer.

15

EXAMPLE 3

Tyrosine Hydroxylase Staining of Sections

Sections prepared according to the procedure described in Example 2 were stained for tyrosine hydroxylase by the procedure described below.

20

Day 1

1. Wash sections in 0.1 M PBS pH 7.4, two times, 5 minutes each.
2. Incubate in 3% hydrogen peroxide in distilled water for 5 minutes to block endogenous peroxidase activity.
- 25 3. Wash briefly in distilled water.
4. Wash in PBS three times, 5 minutes each.
5. Incubate in PBS with 3% goat serum (normal goat serum, Vector Labs; Burlingame, CA) for 30 minutes (to block non-specific staining when using a primary rabbit antibody and a secondary goat anti-rabbit antibody).
- 30 6. Wash in PBS three times, 5 minutes each.
7. Incubate in tyrosine hydroxylase antibody (Eugene Tech International; Allendale, NJ at 1:500 dilution or East Acres; Southbridge, MA at 1:2000 dilution for rat brains and 1:2500 dilution for mouse brains) diluted in

35

27

PBS with 1% goat serum and 0.1% Triton X-100 overnight at room temperature, agitated on a fish-tank aerator.

Day 2

- 5 8. Wash in PBS with 1% goat serum three times, 5 minutes each.
9. Incubate in Biotinylated anti-Rabbit IgG (Vector, Burlingame, CA reconstituted in 1 ml, use 1:300 dilution in PBS) for 1 hour.
- 10 10. Wash in PBS with 1% goat serum three times, 5 minutes each.
11. Incubate in ABC solution (Vector, Burlingame, CA dilute each solution A and B 1:100 in PBS, then let sit for 30 minutes before incubation) for 1 hour.
12. Wash in PBS three times, 5 minutes each.
- 15 13. Incubate in 3,3 diaminobenzidine (DAB) substrate (Litton Bionetics, Durham, NC; reconstitute in 1 ml 0.01 M phosphate buffer (PB) [use 0.1 M phosphate buffer diluted 1:10], then dilute DAB 1:10 with 0.01 M PB, filter and add 2 μ l/ml of 30% Hydrogen Peroxide) for 10 minutes.
- 20 14. Wash in tap water.
15. Mount the floating sections from PBS on subbed slides, (slides dipped in 0.25% chromium potassium sulfate and 2.5% gelatin in distilled water, then dried) dry, wash in distilled water, dehydrate in 95% EtOH 2 minutes, 25 100% EtOH two times, 2 minutes each, then Hemo-De (Xylene substitute, Fisher Corporation, Springfield, NJ) three times, 2 minutes each, and coverslip using Protexx mounting media (VWR, San Francisco, CA).
- 30

EXAMPLE 4

*Quantitative Analysis of TH-Positive Cell Bodies
in Sections from Grafted Brains*

- 35 Tyrosine hydroxylase (TH) positive staining was used as a marker for those neurons which contain dopamine. TH-positive cell bodies in the graft area which had been stained by the procedure

30

described in Example 3 were quantitated by the procedure described below.

1. All TH-positive cell bodies are counted in every third section throughout the graft using a Zeiss microscope at 100× magnification.
2. The section thickness is measured at 1000× using an oil immersion objective. Thickness in microns is found by focusing on the top of the section, recording the micrometer reading on the focusing knob of the microscope, and then focusing through the section to the bottom and computing the difference in readings. The thickness is measured in two different areas on five representative sections.
3. The cell body length is measured at 1000× magnification using an ocular micrometer or the video image analyzer. Ten typical cell body lengths are measured per section on ten representative sections. Due to shrinkage in the section thickness and cell diameter during histological preparation, these measurements must be taken at the time of counting.
4. Approximation of the number of cells in the sections not counted is done using the formula being:
$$A_1 = A + [(B-A)/3] \text{ and } A_2 = A + 2 [(B-A)/3]$$

where: A = the number of cells counted in the first section, and B = the number of cells counted in the second section, and A₁ and A₂ are the number of cells from the sections not counted between A and B.
5. Abercrombie correction for double counting cell in adjacent sections was used to correct the approximation. The formula is:
$$\text{corrected number} = (\text{experimental cell number}) \cdot [(\text{average section thickness}) / (\text{average cell diameter} + \text{average section thickness})]$$

31

EXAMPLE 5

Implantation of Progenitor Cell Cultures In Vivo

Grafts of cultured fetal pig progenitor cell cultures of this invention function in the Parkinsonian rat model. (The
5 Parkinsonian rat model was described by Strecker et al., *Exp. Brain Res.* 76:315-322 [1989] and Brundin et al., *Neurosci. Lett.* 61:79-84 [1985]. Those articles are incorporated herein by reference in their entirety.) Donor tissue was dissected from the ventral mesencephalon of stage 15-18 fetal pigs (21-24 day fetal
10 pigs), enzymatically dissociated, mechanically triturated, and cultured as described above for aggregate cultures for 15 days. Typically, 3×10^4 cells were plated per well; and, after 6-150x proliferation, the cells were transplanted (1 well/rat). The cultured tissue was injected directly into the dopamine-denervated striata of host rats. By 16 weeks post-implantation, eleven of 20
15 grafted rats have shown behavioral recovery in the amphetamine-induced rotation test. Histological analysis revealed very large grafts containing numerous dopamine neurons as identified by tyrosine hydroxylase (TH) immunohistochemistry according to the procedure described in Examples 1-4.
20

The average density of the TH-positive neurons in functioning grafts was found to be greater than 100 cells/mm². Most commonly, TH-positive neurons were found to be situated at the graft periphery. Occasionally, rosette-like structures were
25 observed within the grafts.

A parallel experiment combining immunohistochemistry and autoradiography has shown that when such cultures are labeled for 2 days *in vitro* with ³H-TdR (days 5-7) and grafted at day 7, numerous TH-positive grafted neurons containing label are found at
30 4 weeks post-grafting. That experiment is described in Example 6.

EXAMPLE 6

Proliferation of Progenitor Cell Cultures In Vitro

1. Donor tissue was dissected from the ventral
35 mesencephalon of stage 16 fetal pigs, enzymatically dissociated, and cultured as described for aggregate cultures for 7 days.

32

2. From day 5 to day 7, the cells were labelled with tritiated thymidine, at 0.1 μ Ci/ml (New England Nuclear, 20 Ci/mM, 1 mCi/ml, Boston, MA)
3. On day 7, medium was removed, cells were washed three times with HBSS, and transplanted as described into nude mice.
4. Brains were sectioned as described after 4- and 8-week transplant times.
5. Sections were stained for TH as described.
6. Slides were prepared for autoradiography: slides were dipped into NTB2 (1:1 with H₂O) (all reagents: Kodak, Rochester, NY), and air dried in the dark.
7. Slides were exposed at 4°C for 2 weeks.
8. Slides were warmed to room temperature, and developed in 50% Dektol for 1 minute.
9. Slides were rinsed in H₂O for 10 seconds.
10. Slides were fixed in 25% Kodafix for 4 minutes.
11. Slides were rinsed in H₂O for 10 minutes before drying and coverslipping.
12. TH(+) cells were counted, and the percentage of those cells which had incorporated label into their nuclei was determined.
13. 50% of all TH(+) cells had incorporated thymidine between days 5 and 7 in culture.

EXAMPLE 7

Minimum TH(+) Cell Density Required For Cure

1. Twenty-seven ablated rats were transplanted with stage 15-18 porcine tissue (day 21 to 24), either fresh or aggregated in culture, by techniques described.
2. The rats were analyzed for function by the procedure described in Strecker et al., *Exp. Brain Res.* 76:315-322 (1989) during a 16-week period post-implantation.
3. The total number of TH(+) cells in each graft was counted as described.

33

4. The area of the graft in each section was calculated with the use of Vidometric 150 software (American Innovision, San Diego, CA).
5. The total volume of each graft was calculated using the same formula used for determining the total number of TH(+) cells in the graft, as described.
6. The number of TH(+) cells/mm³ was determined for each graft.
7. The results indicated that for 100% functional recovery at least 100 TH(+) cells must be present in each mm³ of tissue.
8. Comparison of the group of transplants which showed 100% functional recovery to the group of transplants which showed either partial or no functional recovery by a Mann-Whitney test showed that the densities of the 2 groups are significantly different ($p < 0.0005$).

EXAMPLE 8

In Vitro Induction of Differentiation

Eight replicate aggregate cultures of human neuron progenitor cells prepared as described above were switched from initial medium to growth medium on day 5. On day 14, the following concentrations of potential differentiation agents, retinoic acid and di-butyryl cyclic AMP (dbc-AMP) were added to the cultures.

Retinoic acid ($\times 10^{-7}$ M): 0; 0.2; 1.0; 5.0

dbc-AMP (mM): 0; 0.4; 2.0; 10.0

Following seven days in the presence of the differentiation agent, the cultures were evaluated for the amount of tyrosine hydroxylase (TH) DNA by standard protein immuno-slot-blot techniques. The cultures without differentiation agent were used as controls. All of the cultures with added retinoic acid had from about 80 to 110% of the amount of TH as the control cultures. For the cultures with dbc-AMP, the amount of TH production was significantly increased as shown below.

34

<u>dbc-AMP (mM)</u>	<u>0.4</u>	<u>2.0</u>	<u>10.0</u>
% of control DNA	400	650	175

5 The study demonstrates that the amount of TH DNA in the cultures was significantly increased using dbc-AMP, but was unchanged using retinoic acid.

10 Six replicate samples of two porcine cultures from two different litters (designated 1133-44 and 1016-94) were switched to growth medium at day 5 and grown for 10 days in the absence of a differentiation agent followed by 7 days in the presence of the concentrations of dbc-AMP stated below. The amount of TH/DNA was evaluated by slot-blot as described above. The results are illustrated below.

	Culture	% of Control	
		1133-44	1016-94
	<u>dbc-AMP (mM)</u>		
	0	100	100
20	0.5	125	140
	1.0	130	160
	2.0	175	260
	5.0	275	330
25	10.0	200	200

As shown in the table, the most effective concentration range for dbc-AMP as a differentiation agent is from 2.0 to 5.0 mM.

30

EXAMPLE 9

Analysis of Catecholamines of Neuron Progenitor Cell Cultures

35 The catecholamine content of neuron progenitor cell cultures was studied to characterize changes in catecholamine production following *in vitro* induction of differentiation. An HPLC analysis determined the approximate concentration and ratios of the three

35

major brain catecholamines; dopamine, epinephrine and norepinephrine.

The cell cultures analyzed included a "control" culture. The control culture was freshly isolated cells from ten porcine embryos (21-day ventral mesencephalon) prepared as described in Example 5. The "standard" culture was a neuron progenitor cell culture of this invention prepared as described in Example 5 from the same embryo preparation as the control culture and cultured for two weeks. That culture included approximately one embryo-equivalent of cells. The third culture was a two week progenitor cell culture prepared as the standard culture and then differentiated using 5 mM dibutyryl cyclic AMP for one additional week as described in Example 8 (for a total of three weeks in culture). That culture included approximately one-third embryo-equivalents of cells.

The HPLC analysis determined that the freshly prepared culture did not have detectable amounts of catecholamines. (The HPLC method can detect the presence of 10 picograms of catecholamines.) The standard culture had at least about 100 picograms of catecholamines (at least 100x the catecholamine content per embryo equivalent of freshly isolated cells). The differentiated culture had several fold greater catecholamine content (at least 3x) than the standard culture (at least 10x the catecholamine content per embryo equivalent of the standard culture).

In addition to producing substantially more catecholamines than the standard culture, the differentiated neuron progenitor cell culture produced different proportions of the three major brain catecholamines. The ratio of the concentration of dopamine to epinephrine to norepinephrine for the standard culture and the differentiated culture are shown below.

	<u>dopamine : epinephrine : norepinephrine</u>		
standard	1.00	: 0.85	: 0.49
35 differentiated	1.00	: 0.99	: 0.63

36

This Example demonstrates that the cultures of this invention are biochemically distinguishable from freshly isolated ventral mesencephalon cells from which they were derived. The Example also demonstrates that in addition to the observable differences in the cell cultures following differentiation which are described in Example 8, the cultures also produce more catecholamines having a different ratio of the major brain catecholamines.

37

WHAT IS CLAIMED IS:

1. A culture comprising proliferated mammalian ventral mesencephalon neuron progenitor cells.
- 5 2. The culture of Claim 1 wherein said progenitor cells are porcine.
3. The culture of Claim 1 wherein said progenitor cells are human.
- 10 4. The culture of Claim 1 wherein said culture is capable of curing Parkinsonian symptoms about 4 months following implantation.
5. The culture of Claim 1 wherein said culture comprises cell aggregates.
- 15 6. The culture of Claim 5 wherein said aggregates range in size from about 100 to about 1000 microns.
7. The culture of Claim 5 wherein said aggregates have loci of undifferentiated cells and loci of neurons.
8. A graft comprising mammalian ventral mesencephalon neuron progenitor cells and their differentiated counterparts.
- 20 9. The graft of claim 8 wherein the species of the cells in the graft is the same as the species of the host animal.
10. The graft of claim 8 wherein the species of the cells in the graft is different from the species of the host animal.
11. The graft of claim 8 wherein the species of the cells in the graft is porcine.
- 25 12. A method for evaluating an agent which inhibits or enhances neuroblast proliferation or differentiation or for evaluating the toxicity of an agent on neurons comprising combining said agent with a culture of Claim 1.
- 30 13. A method for producing a culture comprising neuron progenitor cells comprising:
 - a. obtaining ventral mesencephalon tissue from a mammalian embryo at Carnegie stages from 15 through 18;
 - b. dissociation of said tissue to obtain single cells and small cell clusters for culture;
 - 35 c. culturing said single cells and small cell clusters in an initial culture medium which promotes the survival

38

- of neuron progenitor cells which are capable of proliferating in serum-free, defined medium for a sufficient period of time to produce a cell culture containing neuron progenitor cells capable of proliferating in serum-free, defined medium; and
- 5 d. growing said cell culture containing neuron progenitor cells in a medium which maintains neuronal cells.
14. The method of Claim 13 wherein said medium of step (c) is Ham's F12 medium supplemented with Chang's supplement C.
- 10 15. The method of Claim 14 wherein said medium is additionally supplemented with glutamine and superoxide dismutase.
16. The method of Claim 13 wherein said medium of step (d) is N2 medium.
- 15 17. The method of Claim 16 wherein said medium of step (d) is HN2 medium.
18. The method of Claim 13 wherein said period of time is 5 days.
19. The method of Claim 12 wherein said culture is an aggregate culture.
- 20 20. The method of Claim 18 wherein not more than 10^5 cells are seeded per culture.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/07630

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 5/00 U.S.Cl.: 435/240.2, 240.21		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	435/240.2, 240.21; 424/570, 582	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
Databases: DIALOG (Files 55, 311, 312, 154), USPTO Automated Patent System (File USPAT, 1975-1991). See attachment for search terms		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	Brain Research, Volume 332. Issued 1985. Asou et al.. "Mitotic neuro-blasts in dissociated cell cultures from embryonic rat cerebral hemispheres express neurofilament protein". pages 355-357. see the entire document.	1-20
Y	Neurochemical Research, Volume 7. Number 3. Issued 1982. Barakat et al.. "The importance of cell contact for the proliferation of neuroblasts in culture and its stimulation by meningeal extract". pages 287-300. see the entire document.	1-20
Y	Brain Research, Volume 295. Issued 1984. Kriegstein et al.. "Neuron generation in dissociated cell cultures from fetal rat cerebral cortex". pages 184-189, see the entire document.	1-20
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁵ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ³	Date of Mailing of this International Search Report ²	
12 March 1991	18 APR 1991	
International Searching Authority ¹	Signature of Authorized Officer ¹³	
ISA/US	<i>Jasemine C. Chambers</i> Jasemine C. Chambers	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁰ with indication, where appropriate, of the relevant passages ¹¹	Relevant to Claim No ¹²
<u>N</u> Y	Society of Neuroscience Abstracts. Volume 15. Number 2. Issued October 1989. Boss et al.. "Functional transplantation of proliferated fetal pig dopamine (DA) neurons in the Parkinsonian rat model", page 1354. abstract number 533.4.	<u>1.2.8.10.11</u> 3-7.9.12-20
Y	Brain Research. Volume 397. Issued 1986. Kamo et al.. "Functional recovery in a rat model of Parkinson's disease following transplantation of cultured human sympathetic neurons". page 372- 376. see the entire document.	1-20
Y	Experimental Brain Research. Volume 76. Issued 1989. Strecker et al.. "Survival and function of aggregate cultures of rat fetal dopamine neurons grafted in a rat model of Parkinson's disease". pages 315-322. see the entire document.	1-20
Y	Experimental Brain Research. Volume 77. Issued 1989. Huffaker et al.. "Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease". pages 329-336. see the entire document.	1-20
Y	Neuron. Volume 3. Issued July 1989. Calof et al.. "Analysis of neurogenesis in a mammalian neuroepithelium: pro- liferation and differentiation of an olfactory neuron precursor in vitro". pages 115-127. see the entire document.	1-20
Y	Journal of Cell Biology. Volume 107. Number 6 Part 3. Issued 1988. Calof et al.. "Identification of a proliferating neuronal precursor cell in cultures of a mammalian neuroepithelium", page 510a. abstract number 2875.	1-20

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	Neuroscience Letters. Volume 70. Issued 1986. Yoshida et al.. "Subcultured astrocytes suppress the proliferation of neuroblasts in vitro". pages 34-39, see the entire document.	1-20
Y	Nature. Volume 340. Issued 10 August 1989. Temple. "Division and differenti- ation of isolated CVS blast cells in microculture". pages 471-473, see the entire document.	1-20

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.